The aim of the work was to assess the clinical efficacy of flavonoid glycoside derivatives in the therapy of benign and precancerous cervical disease. The study has been performed in Oblast Teaching Hospital of Odessa in 2010–2013. The study enrolled 80 women of reproductive age (mean age 28.4 ± 0.2 years) with confirmed mild to moderate cervical epithelial neoplasia (the main group) and 30 apparently healthy women assessed during prophylactic health check-ups. Human papillomavirus has been quantified in fixed preparations using a standard technique of real-time PCR. Immunohistochemical testing for CD1a was performed with murine monoclonal antibodies diluted 1:25. All of the female patients had dysplasia of squamous cervical epithelium, including CIN I in 27 (54.0 %) cases, CIN II in 15 (30.0 %) cases and CIN III in 8 (16.0 %) cases. In a setting of dysplasia, some of the patients had other genital disease. In 84.5 % of cases, human papillomavirus belonged to the А9 group (types 16, 31, 33, 35, 52 and 58). Using Proteflazid as a part of multimodality treatment had reduced the viral burden of genital papillomavirus infection (by 3.0 lg D50) and facilitated the increase in numbers of antigen-presenting cells. In terms of virustatic and anti-relapse effects, standard therapy was inferior to multimodality regimen with Proteflazid
